AbCellera Biologics annual depreciation and amortization
2019
2020
2021
2022
2023
2024
2025
AbCellera Biologics Depreciation & Amortization Growth & History (ABCL)
AbCellera Biologics's depreciation and amortization was $22.1M for fiscal 2025.
View full AbCellera Biologics company overviewAbCellera Biologics annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $22.1M | −$4.7M | −17.51% |
| 2024 | 2024-12-31 | $26.8M | $2.4M | +10.01% |
| 2023 | 2023-12-31 | $24.4M | −$3.4M | −12.38% |
| 2022 | 2022-12-31 | $27.8M | $13.4M | +92.67% |
| 2021 | 2021-12-31 | $14.5M | $9.6M | +198.82% |
| 2020 | 2020-12-31 | $4.8M | $3.2M | +201.50% |
| 2019 | 2019-12-31 | $1.6M | — | — |
AbCellera Biologics quarterly depreciation and amortization
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $7.0M | $1.5M | +27.79% |
| Q1 2026 | 2026-03-31 | $6.8M | $1.5M | +28.27% |
| Q4 2025 | 2025-12-31 | $7.9M | — | — |
| Q3 2025 | 2025-09-30 | $5.2M | −$31.7M | −85.79% |
| Q2 2025 | 2025-06-30 | $5.5M | −$31.1M | −85.02% |
| Q1 2025 | 2025-03-31 | $5.3M | $487,000 | +10.05% |
| Q3 2024 | 2024-09-30 | $36.9M | $31.2M | +543.75% |
| Q2 2024 | 2024-06-30 | $36.5M | $30.9M | +551.02% |
| Q1 2024 | 2024-03-31 | $4.8M | −$670,000 | −12.15% |
| Q3 2023 | 2023-09-30 | $5.7M | $585,000 | +11.36% |
| Q2 2023 | 2023-06-30 | $5.6M | $724,000 | +14.82% |
| Q1 2023 | 2023-03-31 | $5.5M | $1.5M | +38.20% |
| Q3 2022 | 2022-09-30 | $5.2M | $1.5M | +40.48% |
| Q2 2022 | 2022-06-30 | $4.9M | $1.4M | +38.73% |
| Q1 2022 | 2022-03-31 | $4.0M | $685,000 | +20.73% |
| Q3 2021 | 2021-09-30 | $3.7M | $3.6M | +8841.46% |
| Q2 2021 | 2021-06-30 | $3.5M | $2.6M | +294.40% |
| Q1 2021 | 2021-03-31 | $3.3M | $2.7M | +475.78% |
| Q3 2020 | 2020-09-30 | $41,000 | — | — |
| Q2 2020 | 2020-06-30 | $893,000 | — | — |
| Q1 2020 | 2020-03-31 | $574,000 | — | — |
AbCellera Biologics depreciation and amortization trends
Over the last five fiscal years, AbCellera Biologics's depreciation and amortization increased from $4.8M to $22.1M, a change of $17.3M. The latest reported quarter, Q2 2026, shows $7.0M.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review AbCellera Biologics source filings ↗